Piwnica-Worms
David Piwnica-Worms, Ladue, MO US
Patent application number | Description | Published |
---|---|---|
20080233589 | Complementation Systems Utilizing Complexes of Heteroproteins - The present invention provides heterologous complementation systems and methods of using the systems to detect molecular interactions. In particular, the heterologous complementation systems comprise polypeptide fragments derived from heterologous polypeptides. If a molecular interaction occurs, then the heterologous polypeptide fragments are able to associate and produce a detectable signal. | 09-25-2008 |
20090264355 | METHODS TO TREAT ALZHEIMER'S DISEASE OR OTHER DISORDERS MEDIATED BY AMYLOID-BETA ACCUMULATION IN A SUBJECT - The invention provides methods of delaying the onset, slowing the progression, preventing, or treating Alzheimers disease in a subject. In particular, the invention provides methods of modulating transport of Aβ across the blood brain barrier of the subject. | 10-22-2009 |
20100121031 | MEMBRANE-PERMEANT PEPTIDE COMPLEXES FOR TREATMENT OF SEPSIS - Methods and compositions for treating sepsis and diseases and conditions involving cellular apoptosis using cell membrane-permeant peptide conjugates of a cell membrane permeant peptide together with anti-apoptotic domains of the TCL1 protein are provided. | 05-13-2010 |
20110250145 | BIOLUMINESCENCE IMAGING OF MYELOPEROXIDASE ACTIVITY IN VIVO, METHODS, COMPOSITIONS AND APPARATUSES THEREFOR - Methods of imaging distribution of myeloperoxidase activity in a subject are disclosed. These methods include the use of bioluminescent substrates, including luminol and wavelength-shifted analogues of luminol. Bioluminescent myeloperoxidase substrates that emit light at longer wavelengths compared to luminol are shown to be useful for imaging myeloperoxidase activity in vivo. The disclosed methods can be used for imaging sites of inflammation and other pathological conditions associated with abnormal levels of MPO activity in vivo. Methods of synthesis of luminol analogues are also disclosed. | 10-13-2011 |
David Piwnica-Worms, St. Louis, MO US
Patent application number | Description | Published |
---|---|---|
20090012025 | Methods and Compositions for Treatment of Sepsis - Methods of treatment of sepsis are disclosed. These methods comprise administering to a subject a composition comprising at least one siRNA directed against at least one gene encoding a pro-apoptotic polypeptide. The pro-apoptotic polypeptide, in some aspects, can be other than Fas or caspase-8. In some embodiments, an siRNA can be directed against a pro-apoptotic component of the mitochondrial pathway, such as a pro-apoptotic bcl-2 protein. In some aspects, an siRNA can be directed against a BH3-only bcl-2 protein, while in other aspects, siRNAs can be directed against multi BH domain Bcl-2 family members such as bax and bak. In some embodiments, an siRNA can be directed against a death receptor pathway molecule such as FADD. In various configurations, a composition can also comprise a cationic lipid such as DOTAP, or nanoparticles comprising a cyclodextrin-containing polycation and a polymer such as a poly(ethylene glycol). | 01-08-2009 |
David Piwnica-Worms, Houston, TX US
Patent application number | Description | Published |
---|---|---|
20140343260 | PET/SPECT AGENTS FOR APPLICATIONS IN BIOMEDICAL IMAGING - Tracers that can be used for PET or SPECT imaging of the distribution of Pgp are disclosed. The tracers are metalloprobes that can comprise a radioactive metal ion such as | 11-20-2014 |
Helen Piwnica-Worms, St. Louis, MO US
Patent application number | Description | Published |
---|---|---|
20100311807 | METHODS FOR IDENTIFYING DIABETES AND OBESITY THERAPEUTICS - The invention relates to inhibition of Par-1b kinase activity for treating disorders including diabetes and obesity. The invention also relates to screening for compounds or compositions that inhibit the kinase activity of Par-1b protein, which compounds and compositions are useful in the treatment of diabetes and obesity, as well as preparing compounds for treatment of diabetes and obesity. | 12-09-2010 |